Global Migraine Drugs Market to Grow at 4.3% During 2024-2032, Impelled by Rising Prevalence and Diagnosis

September 10, 2020 | Healthcare

According to the latest report by IMARC Group, titled “Migraine Drugs Market Report by Treatment Type (Abortive Treatment, Preventive Treatment), Drug Type (Triptans, Ergot Alkaloids, NSAIDs, Acetylcholine Inhibitors/ Neurotoxins, Ditans, CGRP mAbs, and Others), Route of Administration (Oral, Injectable, and Others), Distribution Channel (Hospital-Based Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032”, the global migraine drugs market is expected to grow at a CAGR of 4.3% during 2024-2032. Migraine drugs refer to medications that are used to reduce the severity of migraines and prevent future attacks. A migraine is a severe, neurological disease with a debilitating headache, characterized by an intense throbbing or pulsing in one area of the head. It is accompanied by sensitivity to light, sound and smell, visual disturbances such as auras, and nausea or vomiting. Migraine drugs do not cure migraines; instead, they treat or relieve these symptoms. There are certain blood pressure medications, as well as some antidepressants, anti-seizure drugs and herbals that are used to reduce the frequency of migraines.

Global Migraine Drugs Market Trends:

According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of people getting a­ffected by the condition worldwide. This represents the primary factor that has increased the demand for migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving reimbursement policies for migraine medications are also acting as growth-inducing factors. Besides this, healthcare providers have made significant advancements in the diagnosis and treatment of migraine. A more advanced treatment modality with mechanism-based therapies, including supraorbital transcutaneous stimulation (STS) and transcranial magnetic stimulation, has been introduced as a preventive therapy for migraine. Additionally, there are many other drugs with novel mechanisms of action or new therapeutic targets, which are in different development stages.

Market Summary:

  • Based on the treatment type, the market has been bifurcated into abortive and preventive treatment.
  • On the basis of the drug type, the market has been categorized into triptans, ergot alkaloids, NSAIDs, acetylcholine inhibitors/ neurotoxins, Ditans, CGRP mAbs and others.
  • Based on the route of administration, the market has been segmented into oral, injectable and others.
  • The market has been classified on the basis of the distribution channel into hospital-based pharmacies, retail pharmacies and others.
  • Region-wise, the market has been segmented into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Indonesia, Australia and others), Europe (Germany, France, the United Kingdom, Italy, Russia, Spain and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the market has been examined, with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies, Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.
     

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Treatment Type, Drug Type, Route of Administration, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Migraine Drugs Market to Grow at 4.3% During 2024-2032, Impelled by Rising Prevalence and Diagnosis
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More